Global Hemophilia B Market 2015-2019 - Industry Analysis

血友病B治療薬の世界市場2015-2019

◆タイトル:Global Hemophilia B Market 2015-2019 - Industry Analysis
◆商品コード:IRTNTR7234
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月30日
◆ページ数:60
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、血友病B治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、血友病B治療薬の世界市場規模及び予測、疾患管理別分析、パイプライン分析、市場シェア、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About hemophilia B
Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

Technavio’s analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

Technavio’s report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Baxter
• Grifols
• Novo Nordisk
• Pfizer

[Other prominent vendors]
• Alnylam
• Amarna
• Asklepios
• Biogen
• Catalyst Biosciences
• CSL Behring
• Dimension Therapeutics
• Dong-A Scio
• Emergent BioSolutions

[Market Driver]
• Prophylactic treatment
• For a full, detailed list, view our report

[Market challenge]
• High cost of therapy
• For a full, detailed list, view our report

[Market trend]
• New technological advancements
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Disease overview
Understanding the disease
Epidemiology

PART 07: Pipeline portfolio
Key information of few pipeline candidates

PART 08: Market segmentation by disease severity
Mild hemophilia B
Moderate hemophilia B
Severe hemophilia B

PART 09: Market segmentation by disease management
On-demand therapy
Prophylactic therapy
Inhibitor therapy

PART 10: Geographical segmentation

PART 11: Market drivers
Focus on prophylactic treatment
Drugs with prolonged action
Patient assistance programs

PART 12: Impact of drivers

PART 13: Market challenges
High cost of therapy
Low diagnosis rate in developing countries
Complications of available therapies

PART 14: Impact of drivers and challenges

PART 15: Market trends
Advances in technology
Strategic alliances
Development of gene therapy products

PART 16: Vendor landscape
Competitive scenario
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
Baxter
Grifols
Novo Nordisk
Pfizer

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global hemophilia B market 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Global cases of hemophilia B 2010-2013
Exhibit 05: Cases of Hemophilia B by region 2012
Exhibit 06: Cases of hemophilia B by region 2013
Exhibit 07: Global hemophilia B market segmentation by disease severity
Exhibit 08: Global hemophilia B market segmentation by disease severity 2014
Exhibit 09: Treatment of severe hemophilia B 2014
Exhibit 10: Global hemophilia B market segmentation by disease management
Exhibit 11: Share of prophylactic therapy by region 2014
Exhibit 12: Types of prophylaxis
Exhibit 13: Global hemophilia B market segmentation by disease management 2014
Exhibit 14: Global hemophilia B market segmentation 2014
Exhibit 15: Global hemophilia B market segmentation by revenue 2014 ($ billions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
Exhibit 19: Baxter: Key takeaways
Exhibit 20: Grifols: Key takeaways
Exhibit 21: Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
Exhibit 22: Novo Nordisk: Key takeaways
Exhibit 23: Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
Exhibit 24: Pfizer: Key takeaways
Exhibit 25: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 27: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 28: Novo Nordisk: R&D expenditure 2014



【掲載企業】

Baxter, Grifols, Novo Nordisk and Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, uniQure.

【資料のキーワード】

血友病B、血友病B治療薬、医薬品、製薬、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[血友病B治療薬の世界市場2015-2019] (Global Hemophilia B Market 2015-2019 - Industry Analysis / IRTNTR7234)販売に関する免責事項
[血友病B治療薬の世界市場2015-2019] (Global Hemophilia B Market 2015-2019 - Industry Analysis / IRTNTR7234)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆